department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Altimmune, Inc. ($ALT) · pharmadog

PUBLIC COMPANY

$ALTAltimmune, Inc.

Gaithersburg, MD, USupdated 1h ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

0

phase 3

0

catalysts ytd

2

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 2

Alcohol Use Disorder (AUD)

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1) · 8k filing (1)

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Altimmune, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$ALT

SEC CIK

0001326190

country

US

source

sec_tickers

mentioned in

0news items

entity-linker matched

Altimmune, Inc. earnings

Altimmune, Inc.

$ALT — Altimmune, Inc. (ALT) — 8-K filing

Altimmune, Inc.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase2RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)recruitingn=100
phase2IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)completedn=212
phase2HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)terminatedn=87
phase2RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweightactive not recruitingn=100
phase1NasoShield Study of Safety and Immunogenicitycompletedn=145
phase1Pemvidutide (ALT-801) DDI Study in Healthy Volunteerscompletedn=40
phase1NasoShield in Healthy Adults to Study Safety and Immunogenicitycompletedn=43
phase1ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerabilitycompletedn=100

more trials →

Data sources

last refreshed 8m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$ALT3.1950+1.11%

$ALT3.1950+1.11%

$ALT3.1950+1.11%

Insider activity

source: SEC Form 4

open-market buys + sells

Apr 6, 26BUYGILL JOHN· 9,200 sh @ $3.41$31K↗
Apr 1, 26BUYDurso Jerome Benedict· President and CEO15,000 sh @ $3.14$47K↗
Apr 1, 26BUYWEAVER GREGORY L· Chief Financial Officer10,000 sh @ $3.15$31K↗
Mar 6, 26BUYDurso Jerome Benedict· President and CEO20,000 sh @ $3.54$71K↗
Mar 6, 26BUYWEAVER GREGORY L· Chief Financial Officer5,000 sh @ $3.54$18K↗

routine RSU / option mechanics (6)

Feb 26, 26grantWEAVER GREGORY L · Chief Financial Officer111,000 sh
Feb 26, 26grantRoberts M Scot · Chief Scientific Officer222,670 sh
Feb 26, 26grantRoberts M Scot · Chief Scientific Officer95,430 sh
Feb 26, 26grantWEAVER GREGORY L · Chief Financial Officer259,000 sh
Feb 2, 26tax coverRoberts M Scot · Chief Scientific Officer2,329 sh

Feb 2, 26

option exercise

Roberts M Scot · Chief Scientific Officer

7,775 sh